Treatment Of First Patient In Systemic Clinical Trial Of AVI-4658 For Treatment Of Duchenne Muscular Dystrophy

February 23 2009

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced treatment of the first patient in a clinical trial evaluating the systemic delivery of AVI-4658 for the treatment of Duchenne muscular dystrophy (DMD). "We are very pleased to begin the systemic evaluation of our exon skipping drug -- AVI-4658 -- for the treatment of DMD," said Stephen Shrewsbury, M.D.

  • Donate
  • Congenital Muscular Dystrophy

    A group of diseases causing muscle weakness at birth. Several defined genetic mutations cause muscles to break down faster than they can repair or grow. A child with CMD may have various neurological or physical impairments. Some children never gain the ability to walk, while others lose the ability as they grow older. Learn more...
  • Register Now!
  • Events

  • Register Now!
  • Navigation

    Show Sub-Pages | Hide Sub-Pages